Brief: Sema4|Genedx Announces Results From Phase 1 Of Seqfirst Study
27/10/2022 14:07
Oct 27 (Reuters) - Sema4 Holdings Corp SMFR.O :
* SEMA4|GENEDX ANNOUNCES RESULTS FROM PHASE 1 OF SEQFIRST
STUDY,
DEMONSTRATING BROAD UTILITY OF RAPID WHOLE GENOME SEQUENCING FOR
CRITICALLY ILL NEWBORNS
Source text for Eikon: ID:nGNX3V7Hys
Further company coverage: SMFR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GeneDx Holdings
See all newsBrief: Genedx Launches New Online Offering For Families To Improve Accessibility Of Exome Testing For Children
GeneDx Holdings Corp reports results for the quarter ended June 30 - Earnings Summary
GeneDx Q2 revenue beats analyst estimates
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys
Brief: Genedx Names Mark Gardner President To Lead Its Next Phase Of Scale And Growth